Clinical observation of Sanjie Prescription in the treatment of moderate risk ground glass pulmonary nodule

Clinical observation of Sanjie Prescription in the treatment of medium-risk ground glass pulmonary nodules

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300070918

Enrollment

Unknown

Registered

2023-04-26

Start date

2023-05-01

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary nodules

Interventions

Experimental group:Sanjie prescription

Control group:None

Eligibility

Sex/Gender

All

Age

35 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? It can meet the diagnostic criteria of medium-risk pure ground glass pulmonary nodules. ? Age 35-80 years old. (3) Voluntary signing of informed consent, voluntary participation in clinical studies, able to truthfully answer questions, adhere to return visits.

Exclusion criteria

Exclusion criteria: ? Those who have been diagnosed with sarcoidosis, tuberculosis or other infectious diseases. ? Patients with serious primary diseases or tumor diseases, such as cardiovascular, cerebrovascular, liver, kidney, and blood. ? Patients with mental diseases such as mania, schizophrenia or other reasons could not cooperate with the observation study. ? Pregnant or lactating women. ? People who are allergic to traditional Chinese medicine, have allergic constitution or are allergic to multiple drugs.

Design outcomes

Primary

Measure	Time frame
chest CT;	—

Countries

China

Contacts

Public ContactJUN MAN

Affiliated Hospital of Weifang Medical University

manjun0229@126.com+86 13335261699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026